Biogen Inc. (BIIB) Q4 2016 Earnings Results

Biogen Beats on EPS, Stock Up 2.07%

Biogen's earnings report shows a positive surprise in EPS, which contributed to a 2.07% increase in stock price. The management's cautious optimism suggests they are focusing on maintaining their competitive edge and investing in future growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$5.04	N/A	+1.41%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their product pipeline and market position. They acknowledged challenges but remained positive about future growth.

Management highlighted strong demand for their products.

They emphasized ongoing investment in research and development.

There was a focus on maintaining market leadership in key therapeutic areas.

Biogen Beats on EPS, Stock Up 2.07%

Key numbers

Management commentary

Biogen Inc.

More earnings this week

Biogen Beats on EPS, Stock Up 2.07%

Key numbers

Management commentary